Tirzepatide vs Adipotide.

Tirzepatide (development code LY3298176) is a synthetic, 39-amino-acid modified peptide engineered as a "twincretin," a single molecule that activates two incretin hormone receptors at once. It carries a C20 fatty diacid side chain that binds serum albumin, extending its half-life to roughly five days and enabling once-weekly subcutaneous dosing. It is the active ingredient in Eli Lilly's FDA-approved products Mounjaro (type 2 diabetes) and Zepbound (chronic weight management and obstructive sleep apnea).

Adipotide (FTPP, also called prohibitin-targeting peptide-1) is an experimental chimeric peptidomimetic designed to destroy the blood supply of white fat rather than act as a hormone. It was developed by Kolonin, Arap and Pasqualini and colleagues as a proof-of-concept anti-obesity agent that targets the vasculature feeding adipose tissue. Adipotide has only ever been tested in animals; it has never completed human clinical trials and is not a medicine. It is discussed here strictly as a preclinical research compound.

Tirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, the first approved agent to engage both incretin pathways. Through GLP-1 receptor activation it enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central pathways; GIP receptor activation contributes additional insulinotropic effects and is thought to influence energy metabolism and adipose tissue handling. Its peptide backbone is more closely modeled on native GIP, and it is biased toward GIP-receptor engagement relative to GLP-1, though the precise contribution of the GIP arm to its clinical effect in humans remains an area of active investigation. The net clinical result is improved glycemic control and substantial reductions in body weight and food intake.

Adipotide links two functional parts: a homing peptide (sequence CKGGRAKDC) that binds prohibitin, a protein found in unusual abundance on the endothelial cells of white-fat blood vessels, and a pro-apoptotic sequence (a KLAKLAK-type domain) that triggers programmed cell death once internalized. By selectively killing the endothelial cells that supply fat depots, the peptide is intended to starve and shrink adipose tissue. This vascular-targeting approach is fundamentally different from appetite- or metabolism-based drugs like GLP-1 agonists. The concept was first demonstrated in rodents before testing in primates.

Human evidence for tirzepatide is unusually robust, anchored by the large randomized SURPASS (diabetes) and SURMOUNT (obesity) programs. In SURPASS-2 (Frias et al., NEJM 2021), tirzepatide produced greater HbA1c and body-weight reductions than injectable semaglutide in type 2 diabetes across all doses. In the placebo-controlled SURMOUNT-1 trial (Jastreboff et al., NEJM 2022), adults with obesity or overweight lost roughly 15–21% of body weight on average depending on dose. SURMOUNT-OSA (Malhotra et al., NEJM 2024) showed reductions in apnea-hypopnea index in patients with obesity and moderate-to-severe obstructive sleep apnea, supporting the December 2024 FDA approval for that indication. A dedicated cardiovascular outcomes trial (SURPASS-CVOT) and the SUMMIT heart-failure-with-preserved-ejection-fraction program have reported results, but long-term hard-outcome data are newer and still being integrated; readers should treat cardiovascular benefit as supported but more recently established than the glycemic and weight findings.

The original concept was shown in a mouse study by Kolonin and colleagues in Nature Medicine (2004), in which targeted ablation of adipose vasculature reduced fat mass. The most cited primate work, by Barnhart and colleagues in Science Translational Medicine (2011), treated spontaneously obese rhesus monkeys with adipotide for 28 days and reported roughly 7-15% body-weight loss along with reduced body fat on imaging and improved insulin resistance, while untreated controls were unchanged. These findings were promising but limited to small animal cohorts. Both studies share the constraints of early preclinical work: small numbers of animals, short exposure, no blinding comparable to a clinical trial, imaging and biochemical surrogates rather than clinical endpoints, and no follow-up long enough to show whether fat loss persists once treatment stops or whether ablated adipose vasculature regenerates. No completed, peer-reviewed human efficacy trials exist, and marketed or clinical human data are absent. All human-facing claims about adipotide therefore rest on animal data only. The gap is total rather than partial: there is no published human pharmacokinetic profile, no established human tolerated exposure, no efficacy signal in people, and no regulatory review of any human dataset. That places adipotide in a different category from approved obesity pharmacotherapy. Drugs such as semaglutide and tirzepatide reached approval through multi-thousand-participant randomised Phase 3 programs with blinded comparators, adjudicated safety events and, in semaglutide's case, dedicated cardiovascular outcome data, and their weight-loss estimates come from human trials rather than extrapolation from monkeys. Any comparison of adipotide's reported primate weight change with those human results is not a like-for-like comparison, and the current literature on adipotide is largely mechanistic and vascular-targeting research rather than obesity therapeutics. Nothing published to date establishes that the approach translates from rodents and monkeys to people at all.

The most common adverse effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, and decreased appetite, typically arising during dose escalation and often diminishing over time. The FDA label carries a boxed warning regarding thyroid C-cell tumors based on rodent studies (the human relevance is unknown), and it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Documented risks include acute pancreatitis, gallbladder disease, acute kidney injury (often via dehydration from GI losses), hypersensitivity reactions, and hypoglycemia when combined with insulin or sulfonylureas. Important unknowns remain around long-term safety, effects of regained weight after discontinuation, use in pregnancy, and potential reduced effectiveness of oral medications (including oral contraceptives) due to delayed gastric emptying.

The pivotal primate study identified dose-dependent renal toxicity, specifically renal tubular changes, as the main safety signal at doses that produced meaningful weight loss; these kidney effects were a major reason human development did not advance. That finding matters because it appeared at exposures tied to the desired effect rather than only at extreme excess, which is the pattern that most often halts a candidate before first-in-human work. Because adipotide has not been through human trials, its safety in people is unknown and unvalidated. No human dose has been shown to be tolerated, there is no characterised human adverse-event profile, no drug-interaction data, and no evidence about what monitoring would even detect harm early. A legitimate first-in-human program for a pro-apoptotic vascular-targeting agent of this kind would require intensive renal function monitoring, careful dose escalation with stopping rules, and independent safety oversight, none of which applies to informal use. Material sold online as research chemical is unregulated and not quality-controlled, meaning the identity, potency, purity, endotoxin content and sterility of the vial are unverified, and there is no manufacturer accountable for a bad batch or any channel for reporting injury. Adipotide is not approved for human use in any jurisdiction, and the combination of a known organ-toxicity signal in primates with an unregulated supply chain is the central safety consideration for this compound.

Tirzepatide is FDA-approved (not investigational): as Mounjaro for type 2 diabetes (May 2022) and as Zepbound for chronic weight management (November 2023) and moderate-to-severe obstructive sleep apnea in adults with obesity (December 2024); it is also authorized in the EU, UK, and other jurisdictions. It is a prescription drug, and compounded or research-grade "tirzepatide" sold outside the regulated supply chain is not FDA-approved and carries quality and safety risks.

Adipotide is a preclinical/research compound with no FDA, EMA, or other regulatory approval for any use. It is not an approved drug or supplement, and no legitimate human therapeutic product exists. Any human use would be unapproved and unstudied.